. "FDA"^^ . "Organic Chemical"^^ . "C2703109"^^ . "An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.NCI" . "AP24534CNNCI" . "943319-70-8"^^ . . . . "Ponatinib"^^ . "PonatinibPTNCI" . "Pharmacologic Substance"^^ . "AP-24534CNNCI" . "Ponatinib"^^ . "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)SNNCI" . "4340891KFS"^^ . "C29H27F3N6O"^^ . . "C95777"^^ . "PONATINIBPTFDA4340891KFS" .